WASHINGTON — Drug makers are about to lose a key ally in Washington.
Republican Sen. Orrin Hatch of Utah, a longtime advocate for the drug industry, announced Tuesday he will retire at the end of his term this year. Across a four-decades-long career in the Senate, Hatch used influential positions atop the Finance Committee, the Health, Education, Labor and Pensions Committee, and the Judiciary Committee to advance the industry’s major policy priorities.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
